Lawmakers try to tackle the mental and emotional effects of wildfires
The Eaton and Palisades fires starting on Jan. 7 burned through large swaths of Los Angeles County, destroying over 11,000 buildings, resulting in 29 deaths and around $30 billion in property damage. Experts and legislators anticipate that the devastation will likely leave lasting emotional and physical scars on residents whose lives were upended by the tragedies.
'As Angelenos continue to recover from the devastating firestorms, the Assembly is moving quickly to help and support residents, including with assistance for mental and behavioral health,' said Assembly Speaker Robert Rivas (D-Hollister)
Assembly Bill 1032, authored by Assemblymember John Harabedian (D-Los Angeles) and supported by Rivas, would require healthcare service plans and insurers to reimburse eligible enrollees for up to 12 annual visits with a licensed behavioral health provider if they live in a county affected by a wildfire-related local or state emergency.
Harabedian said that legislators have put all of their focus on the 'physical rebuilding' but 'haven't prioritized the mental health short-term and long-term effects' of the wildfires.
If the bill is passed and signed into law, the benefits will begin in 2026 and will be available for up to one year after an official state of emergency is lifted.
From Jan. 7 to Jan. 15, according to Harabedian's office, the 988 Suicide & Crisis Lifeline experienced a fivefold increase in the number of calls associated with the Disaster Distress Helpline for the Los Angeles region. The predominant emotions callers reported included 'fear, grief, and a real sense of uncertainty.'
Dr. Le Ondra Clark Harvey, chief executive of the California Behavioral Health Assn. and a supporter of the bill, said the physical symptoms someone might experience during and after a natural disaster could include fatigue, headaches, muscle pain, difficulty falling asleep, brain fog, inability to concentrate and flashbacks.
'Wildfires are not an anomaly for Southern California but the number of wildfires happening at the same time and the level of destruction was really catastrophic compared to wildfires I've seen in my lifetime,' she said. The 'shock of it is more impactful' for residents in urban areas because they can be more 'caught off guard.'
Researchers, according to a 2024 study by Nature Mental Health, examined the relationship between anxiety and wildfires and found an increase in emergency room visits for anxiety disorders after wildfire events in California and other parts of the Western U.S. from 2007 to 2018.
Among the most vulnerable populations during these disasters are children and older adults, Clark Harvey said, and she emphasized the need for continuous care.
'It's important during this time people understand how to take care of themselves,' she said. 'If you're having anything out of the normal impacting your daily functioning in the wake of natural disasters do not wait, address it early.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
3 hours ago
- Forbes
Trump's First Term Degraded Military Health. His Second Must Rebuild It
Recently, Senators McConnell (R-KY) and Coons (D-DE) cosponsored a bill to invest more than $850 billion to strengthen our nation's defense industrial base, upgrade its shipbuilding capabilities, replenish munitions, and support key allies. Although these are worthy goals, Congress and the White House must not overlook the system that safeguards the health of American warfighters - our military's most important asset. Last March, the Chair of the Senate Armed Services Committee, Senator Roger Wicker (R-MS), made pointed remarks at the outset of a hearing on stabilizing the military health system: America's Military Health System Is Unique Unlike the Veterans Health Administration (VHA) or private healthcare systems, military health must always be ready to deploy uniformed healthcare professionals anywhere in the world in support 0f U.S. combat operations and other missions, including peacekeeping and humanitarian assistance. To enable this work, the MHS maintains a network of stateside military hospitals and clinics, supplemented by healthcare purchased from private doctors and healthcare systems to treat active-duty service members, their family members, and military retirees. This second mission reinforces the first. The clinical duties that military doctors, nurses, and other health professionals perform in stateside military hospitals helps keep their skills sharp between deployments. It also allows them to teach and inspire the next generation of military healthcare professionals. In times of conflict, military hospitals receive and treat complex casualties. Finally, the high-quality care to wounded, ill and injured servicemembers as well as their families and military retirees helps the DoD recruit and retain its 'all-volunteer' force. Healthy Forces Are Vital For Battlefield Success Military health has played a key role in American history since the founding of our republic. In the Winter of 1777, General George Washington ordered the inoculation of the Continental Army against smallpox. It was the first time in history that an Army was immunized by command order. Washington also instituted policies on camp cleanliness and took other actions to preserve his army's fighting strength. The principles he established still guide military medicine to this day. Health protection is so important to preserving fighting strength that the U.S. military monitors every unit's 'disease and non-battle injury (DNBI)' rates to evaluate the quality of its leadership and medical support. This discipline paid off in Afghanistan and Iraq. Despite logistical challenges and austere conditions, military medicine drove rates of DNBIs and deaths from severe battlefield wounds to the lowest levels in the history of warfare. It's one of the most remarkable achievements in the history of American medicine. Many of the innovations they pioneered have been adopted by civilian healthcare. Post-War Decisions Eroded Hard-Won Gains Instead of recognizing the value of military health, budget officials in the Pentagon viewed the MHS as little more than an HMO for beneficiaries. As the wars wound down, they began siphoning military health funding and positions for other DoD priorities. As a result, spending on military healthcare flattened, and is now far behind healthcare spending in the VA and our nation overall. During Trump's first term, the Pentagon compounded this error by directing military families and retirees to go elsewhere for treatment. Then, as visits and hospital admissions fell, they downsized or closed many military clinics and hospitals. Even top hospitals, such as Walter Reed and Naval Medical Center San Diego, were left underfunded, understaffed, and underutilized. This weakened the link between stateside care and battlefield care. By the time the Joint Chiefs of Staff realized that privatization had gone too far, the damage was done. In 2023, then Deputy Secretary of Defense Kathleen Hicks issued a directive to reverse course and begin restoring the MHS. What About Now? Today, different leaders are in charge. In the past, Defense Secretary Pete Hegseth has advocated diverting military and veteran healthcare benefits to enhance the Pentagon's "war-fighting capability." Military and veterans' healthcare IS a warfighting capability. It's a major reason why American servicemembers fight so hard, accept such risks and reenlist to do it again. Until recently, they knew that every time they were deployed, their families would be cared for by doctors and nurses who understood the stresses of military life. They were also confident that if anyone in their unit became ill or was wounded in battle, they'd receive the best healthcare in the world, expert rehabilitation, and if needed, long-term care. If the Pentagon resumes its push to privatize the military health system, it will harm the health of our armed forces and diminish their battlefield performance. Two former Hegseth aides said as much in a recent New York Times op-ed: Why You and Trump Should Care About Military Health Although most Americans give little thought to military health, servicemembers, veterans and military retirees know better. If any member of your family, a friend, or a neighbor currently serves in uniform, you should care. If one or more of your children or grandchildren are considering military service, you should care. If you value any of the numerous advances military health has contributed to American medicine throughout our nation's history, you should care. As Commander-in-Chief of our nation's armed forces, President Trump should care, and direct Defense Secretary Hegseth and his senior staff to rebuild our nation's military health system.
Yahoo
8 hours ago
- Yahoo
Lab Equipment Market and Supply Chain Forecasts 2025-2030 Featuring Eppendorf, Beckman Coulter, Agilent Technologies, Thermo Fisher Scientific, Waters Corp. & More
The Lab Equipment Market is projected to grow at 7% CAGR, driven by increased pharmaceutical R&D, rising chronic disease prevalence, and growing demand for biologics Lab Equipment Market Dublin, Aug. 20, 2025 (GLOBE NEWSWIRE) -- The "Lab Equipment Market - Forecasts from 2025 to 2030" has been added to offering. The global lab equipment market foresees significant expansion, projected to grow from USD 19.507 billion in 2025 to USD 27.310 billion by 2030, registering a CAGR of 6.96%. This growth trajectory is underpinned by dynamic factors, anticipated to propel the market. Pharmaceutical R&D investments are a primary catalyst, with global spending reaching USD 280 billion in 2024, focusing on groundbreaking drugs and biologics. Streamlined clinical trial processes, exemplified by the European Medicines Agency's fast-track schemes reducing approval times, emphasize the demand for cutting-edge lab equipment essential for drug discovery. Chronic disease prevalence, including cancer, diabetes, and cardiovascular conditions, further accelerates market demand. In 2024, the U.S. recorded 1.9 million new cancer cases, underlining the urgency for advanced diagnostics and drug development. The rising chronic disease burden globally, particularly in aging populations, intensifies the need for sophisticated lab tools. Biologics, derived from living organisms, represent a rapidly growing market segment, accounting for a substantial portion of the pharmaceutical pipeline in 2024. With 40% of clinical trials targeting biologics, specialized lab equipment becomes indispensable for development and testing, driving market expansion. Segment-wise, the sensing equipment category, including spectrometers and conductivity meters, dominates due to its pivotal role in precise diagnostics and drug development. Biopharmaceutical companies hold the largest market share, bolstered by substantial R&D budgets and specialized equipment requirements. Government and academic institutions also contribute significantly, with increased public funding for health research. Geographically, North America leads with over 35% of global lab equipment revenue, supported by advanced healthcare infrastructure. Meanwhile, Asia-Pacific emerges as the fastest-growing region, buoyed by a rising incidence of chronic diseases and increased pharmaceutical investments. Europe's growth is reinforced by regulatory backing for innovative therapies. Key industry players, including Eppendorf AG and Thermo Fisher Scientific Inc., dominate due to robust brand reputations and innovative product offerings. For instance, in 2023, Thermo Fisher launched advanced spectrometry equipment for biologics research, enhancing precision and driving market leadership. Nevertheless, the market faces challenges such as high costs of advanced equipment and the requisite skilled personnel for operating complex systems. Regulatory requirements often delay market entry, necessitating continuous innovation to meet compliance standards. This report provides: Market insights spanning major and emerging regions, focusing on consumer tendencies and industry verticals. Understanding of strategies employed by global key players. Exploration of market drivers and future trends. Actionable insights for strategic business decisions. Catering to startups, research institutions, SMEs, and large enterprises. Report Highlights: Historical data (2022-2024) and forecast (2025-2030). Analysis of growth opportunities, challenges, and regional trends. Strategies and market share analysis of leading companies. Revenue growth projections by segments and regions. Company profiling, strategic developments, and product information. Lab Equipment Market Segmentation: By Type: Analytical Instruments, General Lab Equipment, Measuring & Monitoring Devices, Specialty Equipment, Support Equipment. By End-User: Academic & Research Institutes, Biopharmaceutical & Pharmaceutical Companies, Healthcare & Diagnostic Labs, Government & Regulatory Bodies, Industrial & Manufacturing, Others. By Geography: North America, South America, Europe, Middle East and Africa, Asia-Pacific. Key Attributes Report Attribute Details No. of Pages 150 Forecast Period 2025-2030 Estimated Market Value (USD) in 2025 $19.51 Billion Forecasted Market Value (USD) by 2030 $27.31 Billion Compound Annual Growth Rate 6.9% Regions Covered Global Key Topics Covered1. EXECUTIVE SUMMARY2. MARKET SNAPSHOT2.1. Market Overview2.2. Market Definition2.3. Scope of the Study2.4. Market Segmentation3. BUSINESS LANDSCAPE3.1. Market Drivers3.2. Market Restraints3.3. Market Opportunities3.4. Porter's Five Forces Analysis3.5. Industry Value Chain Analysis3.6. Policies and Regulations3.7. Strategic Recommendations4. TECHNOLOGICAL OUTLOOK5. GLOBAL LAB EQUIPMENT MARKET BY TYPE5.1. Introduction5.2. Analytical Instruments5.3. General Lab Equipment5.4. Measuring & Monitoring Devices5.5. Specialty Equipment5.6. Support Equipment6. GLOBAL LAB EQUIPMENT MARKET BY END-USER6.1. Introduction6.2. Academic & Research Institutes6.3. Biopharmaceutical & Pharmaceutical Companies6.4. Healthcare & Diagnostic Labs6.5. Government & Regulatory Bodies6.6. Industrial & Manufacturing6.7. Others7. GLOBAL LAB EQUIPMENT MARKET BY GEOGRAPHY7.1. Introduction7.2. North America7.3. South America7.4. Europe7.5. Middle East and Africa7.6. Asia-Pacific8. COMPETITIVE ENVIRONMENT AND ANALYSIS8.1. Major Players and Strategy Analysis8.2. Market Share Analysis8.3. Mergers, Acquisitions, Agreements, and Collaborations8.4. Competitive Dashboard9. COMPANY PROFILES9.1. Eppendorf AG9.2. Beckman Coulter, Inc.9.3. Agilent Technologies, Inc.9.4. Thermo Fisher Scientific Inc.9.5. Waters Corporation9.6. F. Hoffmann-La Roche Ltd9.7. Shimadzu Corporation9.8. Bio-Rad Laboratories, Inc.9.9. PerkinElmer Inc.10. APPENDIX For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Lab Equipment Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
a day ago
- Yahoo
CSL slashes 15% of workforce and offshoots vaccine division
Australia's largest pharmaceutical company CSL will reduce its headcount by 15% and spin off its vaccine division in response to an 'unprecedented level of challenge and volatility'. CSL expects a one-off, pre-tax restructuring cost hit of $700m-$770m in the 2026 financial year. The company has conducted a series of changes across its research & development (R&D) department, operating model, and plasma network. For example, the company closed 22 underperforming plasma centres in August 2025. CSL did not disclose the areas of the company from where the 15% reduction in employee base would be initiated. As of 2024, CSL employs 32,000 people globally. The initiatives are expected to lead to savings of $500m-$550m progressively over the next three years, with the majority achieved by the end of the 2027 financial year. CSL said it would redirect the funds to 'high priority opportunities'. While most of CSL's revenue comes from its blood plasma treatments for rare illnesses, the pharma company is also one of the world's largest influenza vaccine manufacturers. It supplies more than 130 million doses of seasonal influenza doses globally each year in its Afluria, Fluad and Flucelvax brands. CSL also announced a planned spin-off of its vaccine division, known as CSL Seqirus. The company did not disclose a valuation for the demerger, which is slated to be completed in early 2026 and produce a publicly listed company in Australia, but CEO Dr Paul McKenzie said it would help 'reshape and simplify the [core] business'. Profit in the vaccine unit dipped due to reduced demand in the US – a revenue area the company hopes to address in 2026. "We firmly believe that a simplified and focused CSL is best for patients, best for our people, and best for our shareholders,' McKenzie added. The company said it would also buy back A$750m ($486.50m) of shares this financial year, partaking in a wider trend of share buybacks across the global pharma industry. Sanofi and Eli Lilly are both undertaking billion-dollar share buyback programmes. The significant restructuring, announced on CSL's 2025 financial year earnings report, eclipsed what was a positive year for the company. Net profit after tax was $3bn for the past 12 months up to June 2025, a rise of 15% on constant currencies. CSL's headcount reduction and vaccine spinoff dragged shares down 9.5%, from A$271.32 at market close on 18 August to A$245.45 at market open on 19 August. The Australian-listed company has a market cap of A$109.1bn, making it the country's fifth-largest company. In regard to impacts from tariffs, McKenzie said CSL's strategic initiatives would not be impacted due to its heavy US manufacturing presence. His statement echoed wider sentiment shared by big pharma company execs in the Q2 earnings window, many of whom expect minimal impact. Navigate the shifting tariff landscape with real-time data and market-leading analysis. Request a free demo for GlobalData's Strategic Intelligence . "CSL slashes 15% of workforce and offshoots vaccine division" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
